Asset Details
Do you wish to reserve the book?
LEAPT: Lectin-Directed Enzyme-Activated Prodrug Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
LEAPT: Lectin-Directed Enzyme-Activated Prodrug Therapy
Do you wish to request the book?
LEAPT: Lectin-Directed Enzyme-Activated Prodrug Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
LEAPT: Lectin-Directed Enzyme-Activated Prodrug Therapy
2004
Overview
Targeted drug delivery to selected sites allows reduced toxicity, enhanced efficiency and interchangeable target potential [Langer, R. (2001) Science 293, 58-59 and Molema, G. & Meijer, D. K. F., eds. (2001) Drug Targeting (Wiley-VCH, Weinheim, Germany)]. We describe a bipartite drug-delivery system that exploits (i) endogenous carbohydrate-to-lectin binding to localize glycosylated enzyme conjugates to specific, predetermined cell types followed by (ii) administration of a prodrug activated by that predelivered enzyme at the desired site. The carbohydrate structure of an α-L-rhamnopyranosidase enzyme was specifically engineered through enzymatic deglycosylation and chemical reglycosylation. Combined in vivo and in vitro techniques (gamma scintigraphy, microautoradiography and confocal microscopy) determined organ and cellular localization and demonstrated successful activation of α-L-rhamnopyranoside prodrug. Ligand competition experiments revealed enhanced, specific localization by endocytosis and a strongly carbohydrate-dependent, 60-fold increase in selectivity toward target cell hepatocytes that generated a >30-fold increase (from 0.02 to 0.66 mg) in protein delivered. Furthermore, glycosylation engineering enhanced the serum-uptake rate and enzyme stability. This created enzyme activity (0.2 units in hepatocytes) for prodrug therapy, the target of which was switched simply by sugar-type alteration. The therapeutic effectiveness of lectin-directed enzyme-activated prodrug therapy was shown through the construction of the prodrug of doxorubicin, Rha-DOX, and its application to reduce tumor burden in a hepatocellular carcinoma (HepG2) disease model.
Publisher
National Academy of Sciences,National Acad Sciences
Subject
/ Antibiotics, Antineoplastic - pharmacokinetics
/ Antibiotics, Antineoplastic - therapeutic use
/ Botany
/ Doxorubicin - analogs & derivatives
/ Doxorubicin - pharmacokinetics
/ Doxorubicin - therapeutic use
/ Enzymes
/ Glycoside Hydrolases - chemistry
/ Glycoside Hydrolases - genetics
/ Glycoside Hydrolases - metabolism
/ Humans
/ Lectins
/ Ligands
/ Liver
/ Liver Neoplasms, Experimental - drug therapy
/ Liver Neoplasms, Experimental - metabolism
/ Liver Neoplasms, Experimental - pathology
/ Male
/ Mice
/ Prodrugs
/ Rabbits
/ Rats
/ Toxicity
